Proteasome inhibition: A novel approach to cancer therapy

Trends in Molecular Medicine

Volumn 8, Issue 4 SUPPL., 2002, Pages

  Adams, Julian ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ARACHIDONATE 5 LIPOXYGENASE; BORTEZOMIB; CYCLIN A; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLOOXYGENASE 2; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; IRINOTECAN; MYC PROTEIN; NITRIC OXIDE SYNTHASE; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN C FOS; PROTEIN C JUN; PROTEIN P130; PROTEIN P27; PROTEIN P53; PROTEIN TYROSINE PHOSPHATASE; REGULATOR PROTEIN; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR; TYROSINE AMINOTRANSFERASE; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

APOPTOSIS; CANCER THERAPY; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG CLEARANCE; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME STRUCTURE; FEVER; HUMAN; MULTIPLE MYELOMA; PERIPHERAL NEUROPATHY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; THROMBOCYTOPENIA;

ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CLINICAL TRIALS; CYSTEINE ENDOPEPTIDASES; HUMANS; MULTIENZYME COMPLEXES; NEOPLASMS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES;

EID: 0036217332     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4914(02)02315-8     Document Type: Review

References (34)

1. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules
2. Proteasome inhibitors: A novel class of potent and effective antitumor agents
3. Protease inhibitor-induced apoptosis: Accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition
4. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells
5. Ubiquitin-proteasome system and increased sensitivity of B-CLL lymphocytes to apoptotic death activation
6. The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-α-initiated apoptosis
7. Role of p53 in cell cycle regulation and apoptosis following exposure to proteasome inhibitors
8. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts
9. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mande cell lymphoma
10. NF-κB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation
11. NF-κB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis
12. Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids
13. Proteasome inhibition: A new strategy in cancer treatment
14. Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin
15. New insights into role of microenvironment in multiple myeloma
16. Transcription factor NF-κB is constitutively activated in acute lymphoblastic leukemia cells
17. Paclitaxel sensitivity of breast cancer cells with constitutively active NF-κB is enhanced by IκBα super-repressor and parthenolide
18. NF-κB and chemoresistance: Potentiation of cancer chemotherapy via inhibition of NE-κB
19. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-κB inhibition
20. Apoptosis and radiosensitization of Hodgkin cells by proteasome inhibition
21. Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin J
22. Proteasome inhibitors: A novel class of potent and effective antitumor agents
23. Proteasome inhibitor PS-341 inhibits constitutive NF-κB activation and bypasses the anti-apoptotic Bcl-2 signal in human multiple myeloma cells
24. Proteasome inhibition leads to significant reduction of Bcr-Abl expression and subsequent induction of apoptosis in K562 human chronic myelogenous leukemia cells
25. Generation of PS-341-adapted human multiple myeloma cells as experimental tools for analysis of proteasome function in cancer
26. Proteasome inhibition measurements: Clinical application
27. Clinical development of a proteasome inhibitor, PS-341, for the treatment of cancen
28. Phase 1 study of intravenous (I.V.) proteasome inhibitor PS-341 in patients (Pts) with advanced malignancies
29. Dose-dependent inhibition of 20S proteasome results in serum II-6 and PSA decline in patients (PTS) with androgen-independent prostate cancer (AI PCa) treated with the proteasome inhibitor PS-341
30. A phase I trial of the novel proteasome inhibitor PS-341 in advanced solid tumor malignancies
31. PS-341: Phase I study of a ofa novel proteasome inhibitor with pharmacodynamic endpoints
32. PS-341 is active in multiple myeloma: Preliminary report of a phase I trial of the proteasome inhibitor PS-341 in patients with hematologic malignancies
33. Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs
34. Phase II study of PS-341, a novel proteasome inhibitor, alone or in combination with dexamethasone in patients with multiple myeloma who have relapsed following front-line therapy and are refractory to their most recent therapy